Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus - VIVUS

Next Previous
Search
Drug Profile

Tacrolimus - VIVUS

Alternative Names: SPI-026; VI-0106

Latest Information Update: 03 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selten Pharma; Stanford University
  • Developer VIVUS
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In volunteers) in United Kingdom (PO, Capsule)
  • 11 Jul 2018 Phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in United Kingdom (PO) before July 2018
  • 08 May 2018 VIVUS announces intention to submit IND to US FDA for Pulmonary arterial hypertension in the first half of 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top